Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc.
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the Company or Novo), and Clinical Consultants International LLC (CCI), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Agreement (the Agreement) with Sarfez Pharmaceuticals, Inc. (Sarfez), a pharmaceutical research and development company with an FDA-approved edema treatment for patients with heart failure and renal disease.
- Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the Company or Novo), and Clinical Consultants International LLC (CCI), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Agreement (the Agreement) with Sarfez Pharmaceuticals, Inc. (Sarfez), a pharmaceutical research and development company with an FDA-approved edema treatment for patients with heart failure and renal disease.
- CCI, a Novo wholly owned subsidiary, was established in 2006 in Michigan as a local hospital consulting firm.
- Headquartered in Boca Raton, Florida, CCI leverages 30+ years of industry experience and its expert consultants worldwide to support clients.
- Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.